Nonmalignant late effects after allogeneic stem cell transplantation
…, A Locasciulli, E Korthof, J Weis, V Levy… - Blood, The Journal …, 2003 - ashpublications.org
Large numbers of patients now survive long term following stem cell transplantation (SCT).
The late clinical effects of SCT are thus of major concern in the 21st century. Secondary …
The late clinical effects of SCT are thus of major concern in the 21st century. Secondary …
[PDF][PDF] Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study
…, M Ciroldi, S De Miranda, V Lévy… - Journal of Clinical …, 2005 - academia.edu
… Guillaume Thiéry, Élie Azoulay, Michael Darmon, Magali Ciroldi, Sandra De Miranda,
Vincent Lévy, Fabienne Fieux, Delphine Moreau, Jean Roger Le Gall, and Benoıt Schlemmer …
Vincent Lévy, Fabienne Fieux, Delphine Moreau, Jean Roger Le Gall, and Benoıt Schlemmer …
Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review
F Pamoukdjian, T Bouillet, V Lévy, M Soussan, L Zelek… - Clinical Nutrition, 2018 - Elsevier
Background & aims To assess the prevalence of sarcopenia before cancer treatment and its
predictive value during the treatment. Methods We searched MEDLINE via PubMed for …
predictive value during the treatment. Methods We searched MEDLINE via PubMed for …
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular …
…, K Hoang-Xuan, N Cassoux, V Levy… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: To assess the feasibility and efficacy of intensive chemotherapy with
hematopoietic stem-cell rescue (IC + HCR) in patients with refractory or recurrent primary CNS …
hematopoietic stem-cell rescue (IC + HCR) in patients with refractory or recurrent primary CNS …
Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two‐year follow‐up of a …
H Kantarjian, R Pasquini, V Lévy… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: In patients with chronic‐phase chronic myeloid leukemia (CP‐CML), imatinib
resistance is of increasing importance. Imatinib dose escalation was the main treatment …
resistance is of increasing importance. Imatinib dose escalation was the main treatment …
[HTML][HTML] Obesity leads to higher risk of sperm DNA damage in infertile patients
…, P Clément, P Briot, I Berthaut, V Levy… - Asian journal of …, 2013 - ncbi.nlm.nih.gov
There has been a growing interest over the past few years in the impact of male nutrition on
fertility. Infertility has been linked to male overweight or obesity, and conventional semen …
fertility. Infertility has been linked to male overweight or obesity, and conventional semen …
Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series
A Bergeron, D Réa, V Levy, C Picard… - American journal of …, 2007 - atsjournals.org
Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia
and are increasingly used for other indications. Fluid retention, however, including pleural …
and are increasingly used for other indications. Fluid retention, however, including pleural …
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders
…, B Barrou, JP Vernant, M Raphael, V Levy - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: Prognostic studies of posttransplantation lymphoproliferative disorders (PTLDs)
are hindered by the small number of cases at each transplant center. We analyzed …
are hindered by the small number of cases at each transplant center. We analyzed …
Measurement of gait speed in older adults to identify complications associated with frailty: a systematic review
…, E Paillaud, L Zelek, M Laurent, V Lévy… - Journal of geriatric …, 2015 - Elsevier
Several frailty screening tests in older cancer patients were developed but their statistical
performance is low. We aimed to assess whether measurement of usual gait speed (GS) alone …
performance is low. We aimed to assess whether measurement of usual gait speed (GS) alone …
Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas
PURPOSE To evaluate first-line pembrolizumab monotherapy efficacy and safety in patients
with unresectable cutaneous squamous cell carcinomas (CSCCs). PATIENTS AND …
with unresectable cutaneous squamous cell carcinomas (CSCCs). PATIENTS AND …